Senior Medical Science Liaison

Who We AreCogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Top-line results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST are expected in 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Our Teamhttps://cogent.culturehq.com

The Medical Science Liaison role is focused on our lead clinical development program, bezuclastinib.  The primary specialties for outreach and engagement include oncology (solid tumors/sarcoma; Gastrointestinal Stromal Tumor, GIST), hematology/oncology (across the spectrum of NonAdvanced Systemic Mastocytosis and Advanced Systemic Mastocytosis), and allergy and immunology (NonAdvanced Systemic Mastocytosis), in the assigned territory.  In the peri-product-launch period, select MSL/Sr MSL team members will partner with a cross-functional team to develop strategic, scientifically accurate, and balanced value and evidence plans that will be leveraged for scientific discourse in the field with HCPs and may also expand to support of interactions with payer audiences in collaboration with the commercial team. Another important aspect of this role is to partner with team members responsible for Patient Advocacy to ensure the patient’s perspective is appropriately and adequately included in scientific communications to underscore patient goals and objectives that aims to advance care across the healthcare spectrum and, ultimately, to improve health outcomes.  Patient-centricity is a core tenet of Cogent’s approach with all stakeholders, both internal and external. The successful MSL/Sr MSL candidate is someone who thrives in a fast-paced environment and is passionate about making an impact on the lives of patients with unmet medical needs.  This is an amazing time to join Cogent as we move towards the potential commercialization of bezuclastinib.  Reporting to the Area Director, US Field Medical Affairs, who will have a direct reporting line to the SVP Medical Affairs/Chief Patient Officer and collaborative engagement with the Medical Affairs and Patient Advocac team members, this role will be on the forefront of educational awareness and building a collaborative and supportive network of HCP-specialists engaged with Cogent and aligned with our core objectives and strategic priorities.   

Responsibilities

• Manage the assigned territory as a scientific and medical expert in the areas of GIST and Systemic Mastocytosis. 
• Support the strategic priorities and imperatives established in collaboration with the cross-functional Medical Affairs and Patient Advocacy team and based on the Cogent’s corporate goals in support of on-going and emerging clinical development programs and, ultimately, commercially available therapeutics.
• Develop and implement a territory strategy and is accountable to engage in compliant, accurate, and data-driven scientific exchange about our clinical development programs in the HCP-specialist areas relevant to the bezuclastinib program and as described above.    
• Lead external communication with a range of thought leaders, subject matter experts, and other HCPs to obtain important insights about current practice, treatment landscape, emerging clinical and scientific data, and competitive intelligence.
• Cultivate a network of experts for Cogent Biosciences disease areas of focus and establish thought leader development plans while ensuring broad awareness of the company and the bezuclastinib program within the HCP-specialist community in the assigned territory. 
• Assist with the facilitation of investigator-initiated research concepts identified through field engagement with relevant researchers in areas of interest aligned with input from the Bezuclastinib Strategy Team and leadership. 
• Remain current on training and adhere to corporate and healthcare compliance, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical information
• Establish and